scholarly journals A perspective review of deadly viral diseases: An era of viruses

Author(s):  
Abhishek Sharma ◽  
Sarita J. Bhyan ◽  
Abdul Malik

This review article overviewed briefly about the era of deadly viruses. Humans have been combating viruses since before our species had even evolved into its recent form. In some cases of viral infections, vaccines and antiviral drugs have allowed us to treat infections from spreading broadly, and have facilitated to patient recover. But it is far from over to fight the viruses. In recent decades, a number of viruses have sprung from animals to humans and have caused massive outbreaks, claiming thousands of lives such as the virus that led to the 2014-2016 Ebola outbreak in West Africa kills up to 90% of the population, making it the deadliest member of the Ebola family. But there are some viruses that are equally deadly, and some are even more deadly. Some viruses, including the novel coronavirus currently undergoing global outbreaks, have a low mortality rate but still pose a serious health risk as we have no means of access to the health facilities and scarcity of resources and infrastructure. Here we are reporting such type of ten deadly viruses. those have infected humans within last 50 years.

2020 ◽  
Vol 7 (4) ◽  
Author(s):  
Mehrdad Mohammadi ◽  
Tim Sandle ◽  
Sajad Rajabi ◽  
Ahmad Khorshidi ◽  
Ahmad Piroozmand

: The novel Coronavirus Disease 2019 (COVID-19) appeared as an emerging respiratory disease in December 2019 in Wuhan, Hubei province, China, and then spread rapidly worldwide, being declared a pandemic on March 11, 2020. Researchers are attempting to discover specifically designed antiviral treatments for COVID-19. Several therapeutic agents such as Interferon-α, Lopinavir/Ritonavir, Ribavirin, Chloroquine, Chloroquine phosphate, Hydroxychloroquine, Arbidol, Favipiravir, Remdesivir, Darunavir, Imatinib, Teicoplanin, Azithromycin, COVID-19 convalescent plasma, other potential antiviral drugs, and Chinese herbal agents are now being clinically studied to examine both pharmaceutical efficacy and safety for COVID-19 treatment in several countries. Some favorable results from these studies have been obtained to date. This review article summarizes and reiterates drugs that are potentially efficient against COVID-19.


Author(s):  
Mohamed Ibrahim Elzagheid

: Nucleosides and their analogues have been in use for many years and have become essential for treating patients with viral infections. Many additional nucleoside drugs have been approved over the past decades. This strongly demonstrates how important these compounds are and the crucial role they play. Given that a significant amount of research and literature has been documented regarding nucleoside analogues, this review article mainly focuses the discussion on nucleosides and nucleoside analogous that have proven to play significant role or be emerging in the treatment of known viral infections. This covers the names, structures, applications, toxicity, and mode of action of relevant nucleoside analogues.


Author(s):  
Bogna Grygiel-Górniak

AbstractThe majority of the medical fraternity is continuously involved in finding new therapeutic schemes, including antimalarial medications (AMDs), which can be useful in combating the 2019-nCoV: coronavirus disease (COVID-19). For many decades, AMDs have been widely used in the treatment of malaria and various other anti-inflammatory diseases, particularly to treat autoimmune disorders of the connective tissue. The review comprises in vitro and in vivo studies, original studies, clinical trials, and consensus reports for the analysis, which were available in medical databases (e.g., PubMed). This manuscript summarizes the current knowledge about chloroquine (CQ)/hydroxychloroquine (HCQ) and shows the difference between their use, activity, recommendation, doses, and adverse effects on two groups of patients: those with rheumatic and viral diseases (including COVID-19). In the case of connective tissue disorders, AMDs are prescribed for a prolonged duration in small doses, and their effect is observed after few weeks, whereas in the case of viral infections, they are prescribed in larger doses for a short duration to achieve a quick saturation effect. In rheumatic diseases, AMDs are well tolerated, and their side effects are rare. However, in some viral diseases, the effect of AMDs is questionable or not so noticeable as suggested during the initial prognosis. They are mainly used as an additive therapy to antiviral drugs, but recent studies have shown that AMDs can diminish the efficacy of some antiviral drugs and may cause respiratory, kidney, liver, and cardiac complications.


2021 ◽  
Vol 4 (11) ◽  
pp. RV1-RV5
Author(s):  
Najmus Sahar ◽  
Pradeep Tangade ◽  
Vikas Singh ◽  
Surbhi Priyadarshini ◽  
Debashis Roy

The novel coronavirus outbreak is a contagious disease affecting the countries around the world. The quick advancing nature of pandemic has gripped the entire community making it a public health emergency. Infection control preventive measures are necessary to prevent it from further spreading. Medical practitioners, health care workers and Dentists are at high risk of acquiring and transmission of infection. The virus transmission occurs through respiratory tract, aerosols and droplets. Clinical manifestations of virus vary from mild to severe sickness. This review article mainly emphasizes on all the information collected to date on the virus, and future recommendations for dental settings to manage the further spread of this virus.


2021 ◽  
Author(s):  
Sajjad Eslamkhah ◽  
Nazila Alizadeh ◽  
Khalil Hajiasgharzadeh ◽  
Masoud Eslamkhah ◽  
Ahad Mokhtarzadeh ◽  
...  

A series of cases of pneumonia occurred in China in late 2019. For this type of coronavirus, the WHO formally identified the condition as a coronavirus disease 2019 (COVID-19). They announced that this disease is the recent main concern of health problems in the world. Transfer of this novel coronavirus (nCoV) from human to human exists predominantly among family members, who have close contact with each other. This review article is provided based on the recent findings of COVID-19, which were retrieved by searching PubMed, Google Scholar, Scopus, and Web of Science until December 2020. Here, we highlighted the coronaviruses types, COVID-19 symptoms, epidemiology of the disease, transmission ways, and nCoV related pneumonia pathogenesis and continue with characteristic features and treatment methods. While no approved treatments are available for this type of infection therapy but several drugs may have potential benefits. It seems that identifying the detailed characteristics of the novel coronavirus disease offers the foundation for further research into the production of effective anti-COVID-19 drugs and vaccines.


2021 ◽  
Vol 12 ◽  
Author(s):  
Gianmarco Bellucci ◽  
Virginia Rinaldi ◽  
Maria Chiara Buscarinu ◽  
Roberta Reniè ◽  
Rachele Bigi ◽  
...  

Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex interactions between the host’s genetic background and several environmental factors that result in dysimmunity against the central nervous system. An old-aged association exists between MS and viral infections, capable of triggering and sustaining neuroinflammation through direct and indirect mechanisms. The novel Coronavirus, SARS-CoV-2, has a remarkable, and still not fully understood, impact on the immune system: the occurrence and severity of both acute COVID-19 and post-infectious chronic illness (long COVID-19) largely depends on the host’s response to the infection, that echoes several aspects of MS pathobiology. Furthermore, other MS-associated viruses, such as the Epstein-Barr Virus (EBV) and Human Endogenous Retroviruses (HERVs), may enhance a mechanistic interplay with the novel Coronavirus, with the potential to interfere in MS natural history. Studies on COVID-19 in people with MS have helped clinicians in adjusting therapeutic strategies during the pandemic; similar efforts are being made for SARS-CoV-2 vaccination campaigns. In this Review, we look over 18 months of SARS-CoV-2 pandemic from the perspective of MS: we dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS-CoV-2 infection, and discuss present evidence on COVID-19 and its vaccination in people with MS.


Author(s):  
Jurica Arapović ◽  
Siniša Skočibušić

The novel coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still progressing and has been recorded in more than 210 countries and territories worldwide. In Bosnia and Herzegovina, the first cases of COVID-19 were detected on 5th of March 2020 in the entity of Republic of Srpska and 9th of March 2020 in the entity of Federation of Bosnia and Herzegovina. Up until the 16th of May 2020, more than 2,200 COVID-19 cases were recorded in both entities, with a mortality rate of 5.8% (131 out of 2231 cases). The aim of this ongoing study is to present the current epidemiological and sociodemographic parameters of 380 COVID-19 patients diagnosed at the University Clinical Hospital Mostar (UCH Mostar) during the first two months of the COVID-19 pandemic. Out of 380 patients, 60 (15.8%) of them required hospitalization. The mortality rate was 5% (19/380). The highest mortality rate of 15.2% (12/79) was recorded in the patients age ≥65 years. In addition to this single-centre experience of the ongoing COVID-19 pandemic, we discuss the epidemiological measures imposed in Bosnia and Herzegovina, with emphasis on the restrictive ones. The COVID-19 pandemic is still ongoing in Bosnia and Herzegovina.


2021 ◽  
Author(s):  
Mayank Kapoor ◽  
Prasan Kumar Panda ◽  
Vivek Mohanty

Most viral infections have limited treatment options available and the same holds for COVID-19, its causative agent being the SARS-CoV-2 virus. Drugs used in the past against Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) viruses, which belong to the same family of viruses as the novel Coronavirus included ribavirin, interferon (alfa and beta), lopinavir-ritonavir combination, and corticosteroids. There remains controversy regarding their efficacy to date, except for the last one. Hence, large-scale multicentric trials are being conducted involving multiple drugs. Chloroquine and hydroxy-chloroquine were initially taking the race ahead but have now been rejected. Remdesivir was a promising candidate, for which the FDA had issued an emergency use authorization, but now is not recommended by the WHO. Convalescent plasma therapy had promising results in the early severe viremia phase, but the PLACID trial made an obscure end. Only corticosteroids have shown demonstrable benefits in improving mortality rates among severe COVID-19 cases. Many new modalities like monoclonal antibodies and tyrosine kinase inhibitors are discussed. In this chapter, we review the therapeutic drugs under investigation for the COVID-19 treatment, their mode of action, degree of effectiveness, and recommendations by different centers regarding their use in current settings.


Author(s):  
Roshni Kumari ◽  
Kumari Pragati Nanda ◽  
Hena Firdaus ◽  
Soumen Dey

The outbreak of coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is declared pandemic by World Health Organization (WHO) keeping in view its infection rate and toxicity level. The entire world is struggling hard to survive the prevailing health emergency. The authors realise the urgent need of contributing an overview of the present scenario to the researchers who are breathlessly trying to combat this pandemic situation. This review aimed at binding all the scattered data and research available till now on COVID-19 disease starting from its origin to transmission and spread through environmental factors till treatment and the safety measures that should be implemented. This article would possibly help the readers by providing an outlook of current scenario on various perspectives of COVID-19 disease at a single glance. The types, origin and toxicity caused are discussed in brief. The role of contaminated aerosols (viral-laden smoke from tobacco, cigarettes), wastewater, fomites, human and faecal matter are important in spreading the novel coronavirus in the environment. There is no specific treatment till date but clinical trials and diagnosis on several known drugs are on-going. The precaution and safety measures could hopefully reduce number of infections and mortality. The number of infected cases confirmed till 2 August 2020 was 17660523 with 680894 deaths in the world. We tried in this review article to summarize the scattered data available on biochemistry of SARS-CoV-2, environmental spread of virus and the safety measures to combat COVID-19 pandemic.


Sign in / Sign up

Export Citation Format

Share Document